Individual stocks making sudden moves
AppLovin（$APP ）：Q3 revenue of 2.185 billion (up 55% year over year, beating expectations) and net profit of 1.439 billion (up 72% year over year); added 3.2 billion in buyback authorization. Shares rose 31% in a single day. Goldman Sachs raised its price target to $445.
INOVIO（$INO.US ）：The FDA granted accelerated approval to VOCERYQ (the first DNA medicine approved in the United States); shares rose 214% (11/2).
Amivantamab + hyaluronidase (Rybrevant Faspro, Johnson & Johnson): On 11/5, the FDA granted accelerated approval for relapsed or metastatic head and neck squamous cell carcinoma; ORR was 42%.
NVIDIA：Earnings date set for 11/17, the next major catalyst.
AppLovin（$APP ）：Q3 revenue of 2.185 billion (up 55% year over year, beating expectations) and net profit of 1.439 billion (up 72% year over year); added 3.2 billion in buyback authorization. Shares rose 31% in a single day. Goldman Sachs raised its price target to $445.
INOVIO（$INO.US ）：The FDA granted accelerated approval to VOCERYQ (the first DNA medicine approved in the United States); shares rose 214% (11/2).
Amivantamab + hyaluronidase (Rybrevant Faspro, Johnson & Johnson): On 11/5, the FDA granted accelerated approval for relapsed or metastatic head and neck squamous cell carcinoma; ORR was 42%.
NVIDIA：Earnings date set for 11/17, the next major catalyst.